This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma. Patients will receive hypofractionated radiotherapy with concurrent chemotherapy. Methylprednisolone will be administered daily during radiotherapy at a dose of 2 mg/kg.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Hypofractionated radiotherapy
weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
Sun yat-sen University Cancer Center
Guanzhou, Guangdong, China
RECRUITINGObjective response rate
The percentage of patients who achieve complete remission or partial remission after chemoradiotherapy
Time frame: 1-2 months after chemoradiotherapy
Progression-free survival
From the start date of initial treatment to progression, death or last follow-up
Time frame: 2-year
Overall survival
From the start date of initial treatment to death or to last follow-up.
Time frame: 2-year
Toxicities using the CTCAE 5.0
Toxicities were evaluated using the CTCAE 5.0
Time frame: 1 year after treatment
Quality of life scores
Quality of life assessed by QLQ-C30
Time frame: 1 year after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.